Skip to main content

Spero Therapeutics, Inc.

SPRO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001701108

No open-market purchases or sales by Spero Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $47.5M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Spero Therapeutics, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of SPRO: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders9589−6
Shares18.6M17.5M−1.06M (−5.7%)
Value$273.1M$244.2M−$28.9M (−10.6%)

New holders (14)

Institutions that held Spero Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to SPRO in Q2 2021
InstitutionSharesValue% of portfolio
Summit Global Investments13,100$183.0K0.01%
ProShare Advisors LLC11,608$162.0K0.00%
State Board of Administration of Florida Retirement System11,007$154.0K0.00%
ExodusPoint Capital Management, LP10,933$153.0K0.00%
Voya Investment Management LLC10,124$141.0K0.00%
Patriot Financial Group Insurance Agency, LLC4,750$66.0K0.01%
Bedel Financial Consulting, Inc.3,837$54.0K0.02%
Institutional & Family Asset Management, LLC2,500$35.0K0.01%
Simplex Trading, LLC507$7.00K0.00%
C M Bidwell & Associates Ltd372$5.00K0.00%
Laurel Wealth Advisors LLC200$3.00K0.00%
Heritage Wealth Advisors187$2.61K0.00%
BDO Wealth Advisors, LLC75$1.00K0.00%
Aspire Private Capital, LLC100$1.00K0.00%

Sold out (20)

Institutions that held Spero Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.